Pyxis Oncology’s (PYXS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a report released on Tuesday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright also issued estimates for Pyxis Oncology’s Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.85) EPS, FY2028 earnings at ($0.34) EPS, FY2029 earnings at $0.27 EPS and FY2030 earnings at $0.83 EPS.

Other equities analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Stephens upped their price target on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada cut their price objective on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, December 18th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $1.39 on Tuesday. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.55. The firm has a market capitalization of $87.33 million, a price-to-earnings ratio of -1.08 and a beta of 1.45. The stock’s fifty day moving average is $1.50 and its two-hundred day moving average is $2.50.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. The firm had revenue of $11.04 million for the quarter, compared to analyst estimates of $0.13 million. As a group, sell-side analysts forecast that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently made changes to their positions in the business. Laurion Capital Management LP increased its stake in Pyxis Oncology by 32.3% in the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after purchasing an additional 1,170,505 shares during the last quarter. Atle Fund Management AB acquired a new stake in Pyxis Oncology in the 4th quarter worth about $710,000. Bank of America Corp DE boosted its stake in Pyxis Oncology by 2,690.9% in the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after buying an additional 593,853 shares during the last quarter. Longaeva Partners L.P. purchased a new stake in Pyxis Oncology in the 3rd quarter valued at about $1,117,000. Finally, Jane Street Group LLC grew its holdings in Pyxis Oncology by 158.8% in the 4th quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock valued at $904,000 after buying an additional 482,310 shares during the period. Institutional investors and hedge funds own 39.09% of the company’s stock.

Key Stories Impacting Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and lifted several EPS estimates (FY2026→-0.95 from -1.28; FY2027→-0.85; FY2028→-0.34; FY2029→0.27; FY2030→0.83) while keeping a $7 price target — a clear bullish signal for future earnings trajectory. Read More.
• Positive Sentiment: Recent quarter: Pyxis reported a beat on the March quarter EPS (-$0.29 vs. -$0.35 consensus) and $11.0M revenue, which supports the analyst upgrades and contributed to improved sentiment. Read More.
• Neutral Sentiment: Analyst coverage remains mixed overall — consensus is still a “Moderate Buy” with an average $7.00 target, but ratings and targets vary across shops (five Buys, one Hold, one Sell), so conviction is not uniform. Read More.
• Negative Sentiment: Insider selling: Director Rachel Humphrey disclosed multiple sales (most recently 13,896 shares at about $1.03). Insider exits can weigh on sentiment even if done for liquidity reasons; SEC Form 4 is filed. Read More. — SEC filing: Read More.
• Negative Sentiment: Some shops trimmed upside: Stifel reduced its price target (reported recently) which could temper momentum from HC Wainwright’s bullish note. Read More.
• Negative Sentiment: Within HC Wainwright’s note there was a small near‑term downgrade to Q2 2026 EPS (to -$0.36 from -$0.32), a mixed signal for the next quarter despite longer‑term upside revisions. Read More.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.